Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Viela Bio, Inc. (VIE) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/15/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
12/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2020 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre..."
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 10, 2020 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights"
11/05/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2020 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre...",
"Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus"
09/15/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 9, 2020 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr..."
08/12/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 13, 2020 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-com...",
"Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights",
"Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus"
04/30/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Viela Bio Announces Election of Rachelle Jacques to its Board of Directors"
03/25/2020 8-K Quarterly results
01/10/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation"
12/11/2019 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 11, 2019 VIELA BIO, INC. Delaware 001-39067 82-4187338 One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland 20878 Registrant's telephone number, including area code: 558-0038 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren's Syndrome"
11/14/2019 8-K Quarterly results
10/09/2019 8-K Quarterly results
10/07/2019 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy